These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11969046)

  • 41. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette-Guerin.
    Granel B; Serratrice J; Morange PE; Disdier P; Weiller PJ
    Clin Exp Rheumatol; 2004; 22(4):481-2. PubMed ID: 15301249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
    Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
    Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Bacillus Calmette-Guerin in superficial bladder cancer: a review.
    Talug C; Brown ET; Zaslau S; Kandzari SJ
    W V Med J; 2009; 105(3):17-9. PubMed ID: 19456033
    [No Abstract]   [Full Text] [Related]  

  • 46. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guérin immunotherapy.
    Poletajew S; Krajewski W; Adamowicz J; Radziszewski P
    Anticancer Drugs; 2019 Jun; 30(5):517-522. PubMed ID: 30870228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Lundholm C; Norlén BJ; Ekman P; Jahnson S; Lagerkvist M; Lindeborg T; Olsson JL; Tveter K; Wijkstrom H; Westberg R; Malmström PU
    J Urol; 1996 Aug; 156(2 Pt 1):372-6. PubMed ID: 8683682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bacillus Calmette-Guerin maintenance treatment in non-invasive bladder tumors: 1 year follow-up results of multicenter URO-BCG-4 trial].
    Galliot I; Le Gall S; Rigaud J; Saint F; Colombel M; Guy L; Wallerand H; Fantoni JC; Staerman F; Irani J; Soulie M; Pfister C;
    Prog Urol; 2013 Apr; 23(5):336-46. PubMed ID: 23545009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [BCG therapy. Its role in the treatment of tumors of the bladder].
    Patard JJ; Chopin DK; Abbou CC
    Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911
    [No Abstract]   [Full Text] [Related]  

  • 53. BCG and the treatment of superficial bladder cancer.
    Moss JT; Kadmon D
    DICP; 1991 Dec; 25(12):1355-67. PubMed ID: 1815434
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
    Lamm DL; van der Meijden PM; Morales A; Brosman SA; Catalona WJ; Herr HW; Soloway MS; Steg A; Debruyne FM
    J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.
    Debruyne FM; Witjes JA; vd Meijden AP
    Arch Esp Urol; 1990; 43 Suppl 2():133-8. PubMed ID: 2096774
    [No Abstract]   [Full Text] [Related]  

  • 56. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pleural effusion after intravesical administration of bacillus Calmette-Guérin.
    Roca Noval A; Cisneros C; García-Pérez FJ; Domingo D
    Arch Bronconeumol; 2017 Dec; 53(12):694-695. PubMed ID: 28476221
    [No Abstract]   [Full Text] [Related]  

  • 59. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
    Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
    J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.